Exploratory observational study on prediction based on PK / PD / PGx of efficacy and safety of palbociclib for patients with inoperable or recurrent breast cancer
Latest Information Update: 28 May 2022
At a glance
- Drugs Palbociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms NCCH1701
- 20 May 2022 Status changed from recruiting to completed.
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.
- 16 Nov 2017 New trial record